Literature DB >> 9183339

Acute stroke care and rehabilitation: an analysis of the direct cost and its clinical and social determinants. The Copenhagen Stroke Study.

H S Jørgensen1, H Nakayama, H O Raaschou, T S Olsen.   

Abstract

BACKGROUND AND
PURPOSE: Stroke represents a major economic challenge to society. The direct cost of stroke is largely determined by the duration of hospital stay, but internationally applicable estimates of the direct cost of acute stroke care and rehabilitation on cost-efficient stroke units are not available. Information regarding social and medical factors influencing the length of hospital stay (LOHS) and thereby cost is needed to direct cost-reducing efforts.
METHODS: We determined the direct cost of stroke in the prospective, consecutive, and community-based stroke population of the Copenhagen Stroke Study by measuring the total LOHS in the 1197 acute stroke patients included in the study. All patients had all their acute care and rehabilitation on a dedicated stroke unit. Neurological impairment was measured by the Scandinavian Stroke Scale. Local nonmedical factors affecting the LOHS, such as waiting time for discharge to a nursing home after completed rehabilitation, were accounted for in the analysis. The influence of social and medical factors on the LOHS was analyzed in a multiple linear regression model.
RESULTS: The average LOHS was 27.1 days (SD, 44.1; range, 1 to 193), corresponding to a direct cost of $12.150 per patient including all acute care and rehabilitation. The LOHS increased with increasing stroke severity (6 days per 10-point increase in severity; P < .0001) and single marital status (3.4 days; P = .02). Death reduced LOHS (22.0 days; P < .0001). Age, sex, diabetes, hypertension, claudication, ischemic heart disease, atrial fibrillation, former stroke, other disabling comorbidity, smoking, daily alcohol consumption, and the type of stroke (hemorrhage/infarct) had no independent influence on LOHS.
CONCLUSIONS: Acute care and rehabilitation of unselected patients on a dedicated stroke unit takes on average 4 weeks. In general, comorbidity such as diabetes or heart disease does not increase LOHS. Efforts to reduce costs should therefore aim at reducing initial stroke severity or improving the rate of recovery.

Entities:  

Mesh:

Year:  1997        PMID: 9183339     DOI: 10.1161/01.str.28.6.1138

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  20 in total

1.  The one-year attributable cost of poststroke aphasia.

Authors:  Charles Ellis; Annie N Simpson; Heather Bonilha; Patrick D Mauldin; Kit N Simpson
Journal:  Stroke       Date:  2012-02-16       Impact factor: 7.914

Review 2.  Thrombolysis, stroke units and other strategies for reducing acute stroke costs.

Authors:  T H Wein; S L Hickenbottom; A V Alexandrov
Journal:  Pharmacoeconomics       Date:  1998-12       Impact factor: 4.981

Review 3.  Reducing the risk of stroke in elderly patients with hypertension: a critical review of the efficacy of antihypertensive drugs.

Authors:  Peter M Nilsson
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  Implementation of antithrombotic management in atrial fibrillation.

Authors:  S J McNulty; D Hutchinson; K J Hardy
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

5.  Recurrent ischaemic stroke hospitalisations: a retrospective cohort study using Western Australia linked patient records.

Authors:  Andy H Lee; Kelvin K W Yau; Kui Wang
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

6.  Variations and determinants of hospital costs for acute stroke in China.

Authors:  Jade W Wei; Emma L Heeley; Stephen Jan; Yining Huang; Qifang Huang; Ji-Guang Wang; Yan Cheng; En Xu; Qidong Yang; Craig S Anderson
Journal:  PLoS One       Date:  2010-09-28       Impact factor: 3.240

7.  A study protocol of a randomised controlled trial incorporating a health economic analysis to investigate if additional allied health services for rehabilitation reduce length of stay without compromising patient outcomes.

Authors:  Nicholas F Taylor; Natasha K Brusco; Jennifer J Watts; Nora Shields; Casey Peiris; Natalie Sullivan; Genevieve Kennedy; Cheng Kwong Teo; Allison Farley; Kylee Lockwood; Camilla Radia-George
Journal:  BMC Health Serv Res       Date:  2010-11-12       Impact factor: 2.655

8.  Evaluation of costs and outcome in cardioembolic stroke or TIA.

Authors:  Yaroslav Winter; Caroline Wolfram; Matthias Schaeg; Jens-Peter Reese; Wolfgang H Oertel; Richard Dodel; Tobias Back
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

9.  The relevance of living supports on antiplatelet adherence and trial participation: the SPS3 trial.

Authors:  Brandy L Lewis; Lesly A Pearce; Thalia S Field; Carole L White; Oscar R Benavente
Journal:  Int J Stroke       Date:  2014-03-24       Impact factor: 5.266

Review 10.  The epidemiology of stroke in the Middle East.

Authors:  Maya El-Hajj; Pascale Salameh; Samar Rachidi; Hassan Hosseini
Journal:  Eur Stroke J       Date:  2016-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.